+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07805369

Open-Label Phase 1 Study of DEM301 to Evaluate Safety and Dose in Adults With Advanced Metastatic Colorectal Cancer

Led by DEM BioPharma, Inc. · Updated on 2026-10-28

60

Participants Needed

2

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating DEM301, an investigational antibody-drug conjugate, in adults with advanced metastatic colorectal cancer who have previously received treatment. This Phase 1, open-label study aims to assess the safety, tolerability, and recommended doses for further research while also examining how the drug behaves in the body and whether it shows signs of activity against cancer. The study has two parts Dose Escalation, where participants receive DEM301 in sequential groups to evaluate safety and identify suitable doses and Dose Expansion, where the drug is further studied at the selected dose or doses. DEM301 is given as monotherapy during both parts. Approximately 60 participants are planned to take part in this multicenter trial. Participants will undergo safety and tolerability assessments, imaging evaluations for tumor response, and laboratory tests to monitor pharmacokinetics, immunogenicity, and pharmacodynamic effects. Researchers will measure dose-limiting toxicities, adverse events, and serious adverse events from the first dose through up to 24 months after the last dose. Additional outcomes include tumor response rates, duration of response, disease control, progression-free and overall survival, and biomarker analyses. Participants are expected to comply with study schedules and provide tumor tissue samples when required.

CONDITIONS

Brief Title

A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer

Research Team

D

DEM301 Study Team

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here